burning for about 15-20 seconds and was hard to breath/ SOB; chest discomfort; Fast heart rate for 10-15 seconds; heart problems; burning for about 15-20 seconds and was hard to breath; Palpitations; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Physician). The reporter is the patient.  A 24 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in deltoid left, administration date 23Aug2021 13:24 (Lot number: FC3183) at the age of 23 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "chest discomfort" (unspecified if ongoing), notes: had similar episodes in the past year but more prominent after she t; "SOB" (unspecified if ongoing), notes: had similar episodes in the past year but more prominent after she t; "Fast Heart rate" (unspecified if ongoing), notes: had similar episodes in the past year but more prominent after she t; "Gustatory rhinitis" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Ipratropium bromide, reaction(s): "Allergy: Ipratropium bromide", notes: Ipratropium bromide nasal spray PRN; Lamotrigine for Seizure disorder, notes: Lamotrigine used for seizure disorder. The following information was reported: CARDIAC DISORDER (non-serious) with onset 23Aug2021, outcome "recovered" (23Aug2021), described as "heart problems"; BURNING SENSATION (non-serious) with onset 23Aug2021, outcome "recovered" (23Aug2021), described as "burning for about 15-20 seconds and was hard to breath"; DYSPNOEA (non-serious) with onset 23Aug2021 20:24, outcome "recovered" (23Aug2021), described as "burning for about 15-20 seconds and was hard to breath/ SOB"; CHEST DISCOMFORT (non-serious) with onset 23Aug2021 18:24, outcome "recovered" (2021), described as "chest discomfort"; HEART RATE INCREASED (non-serious) with onset 23Aug2021, outcome "recovered" (2021), described as "Fast heart rate for 10-15 seconds"; PALPITATIONS (non-serious) with onset Aug2021, outcome "recovered" (2021), described as "Palpitations". Therapeutic measures were not taken as a result of dyspnoea, chest discomfort, heart rate increased, palpitations.  The reporter considered "palpitations" not related to bnt162b2.  Additional information: Caller was a consumer that was calling about the Pfizer Covid-19 Vaccine and reported that about 21 days ago he received the first dose, his second dose is due today. It was not normal after he took the first vaccine. After about 4 hours he experienced heart problems, it was burning for about 15-20 seconds and was hard to breath. He thought that it was part of the side effect until he spoke with his friend and did some research and realized that it is not normal. He said that he was afraid that he will experience worse side effects with the second dose. Caller asked what the side effects are with the second dose and are they worse. He was thinking about cancelling his appointment. Caller declined to provide his mailing address. Caller said that his symptoms resolved after about 4-6 hours. Vaccination Facility Type  was Primary care office. Patient had no History of all previous immunization with the Pfizer vaccine considered as suspect (or patient age at first and subsequent immunizations if dates of birth or immunizations are not available). No events were evaluated at the emergency room visit and Physician Office. Prior Vaccinations, patient did not received any other vaccinations within four weeks prior to the first administration date of the suspect vaccine(s). No Family Medical History Relevant to AE(s). Reporter did not consider the Pfizer product had a causal effect to the adverse event. Reporter stated that Not anaphylactic 5 hours after vaccination (1st dose) chest discomfort, SOB 10-15 seconds, 7 hours after first dose, fast heart rate for 10-15 seconds. Patient had similar episodes in the past year but more prominent after shot. patient did require medical intervention. Patient was not hospitalized. patient was not admitted to an Intensive Care Unit. Reporter provide information on organ involvement: Respiratory, Cardiovascular, Respiratory: Yes, Bilateral wheeze/bronchospasm :No, Stridor: No, Upper airway swelling: No, Respiratory distress: No, Tachypnoea: Unknown, Increased use of accessory respiratory muscles: unknown, Recession: No, Cyanosis: No, Grunting: No, Dry cough: No, Hoarse voice: No, Difficulty breathing (without wheeze or stridor):No, Sensation of throat closure: No, Sneezing: No, Rhinorrhoea, Other: No, Cardiovascular: Yes, Measured hypotension: Unknown, Shock: No. Tachycardia: Unknown; palpitations, Capillary refill time > 3 sec: No, Reduced central pulse volume: No, Decreased level of consciousness: No, Loss of consciousness: No, Dermatological/Mucosal: No, Gastrointestinal: No. Patient had no any other symptoms. Patient did not require the initiation of new medication or other treatment or procedure. the patient did not receive any recent vaccines for any other conditions prior to the event being reported. patient did not receive any recent vaccines for SARS-CoV2 other than Pfizer-BioNTech COVID-19 Vaccine prior to the event being reported.   No Follow-up attempts are possible. No further information is expected.